We are joined by Rakesh Popat, from University College London Hospitals NHS Foundation Trust, at the EHA annual meeting in 2019 to discuss his presentation on the pursuit of antigen targets for relapsed/refractory multiple myeloma.
Questions
1. What are the current treatment options for relapsed/refractory multiple myeloma (MM) and what are their limitations? (0:05)
2. What is the rationale for targeting B-cell maturation antigen in relapsed/refractory MM? (1:20)
3. Could you tell us a little about the structure and mechanism of action of GSK2857916? (2:30)
4. Could you tell us about your phase I study investigating GSK2857916 and its findings? (3:22)
5. What were the findings of the study investigating patient-reported outcomes with GSK2857916? (4:40)
Dr Rakesh Popat has provided consultancy for GlaxoSmithKline Pharmaceuticals Ltd.
Filmed at the European Hematology Association (EHA) 24th congress 2019, Amsterdam, Netherlands.
touchONCOLOGY.com is an independent information resource supporting physicians, clinicians and leading industry professionals in continuously developing their knowledge, effectiveness and productivity, via free-to-access content in multimedia formats.
